stoxline Quote Chart Rank Option Currency Glossary
  
Vericel Corporation (VCEL)
52.02  -0.31 (-0.59%)    03-28 16:00
Open: 52.44
High: 52.5
Volume: 473,781
  
Pre. Close: 52.33
Low: 51.66
Market Cap: 2,512(M)
Technical analysis
2024-03-28 4:54:58 PM
Short term     
Mid term     
Targets 6-month :  61.31 1-year :  71.62
Resists First :  52.5 Second :  61.31
Pivot price 46.54
Supports First :  46.92 Second :  43.47
MAs MA(5) :  49.75 MA(20) :  46.1
MA(100) :  40.52 MA(250) :  36.47
MACD MACD :  1.4 Signal :  0.6
%K %D K(14,3) :  97 D(3) :  95.3
RSI RSI(14): 76.2
52-week High :  52.5 Low :  28.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VCEL ] has closed Bollinger Bands are 82.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 52.54 - 52.81 52.81 - 52.98
Low: 51.02 - 51.38 51.38 - 51.6
Close: 51.51 - 52.05 52.05 - 52.39
Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 29 Mar 2024
Vericel (NASDAQ:VCEL) Reaches New 1-Year High at $51.40 - Defense World

Tue, 26 Mar 2024
Analyst Scoreboard: 5 Ratings For Vericel - Vericel (NASDAQ:VCEL) - Benzinga

Tue, 26 Mar 2024
Vericel Co. (NASDAQ:VCEL) Position Boosted by Legato Capital Management LLC - Defense World

Fri, 15 Mar 2024
Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares - Yahoo Finance

Sun, 03 Mar 2024
US$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results - Yahoo Finance

Fri, 01 Mar 2024
Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 48 (M)
Shares Float 45 (M)
Held by Insiders 0.7 (%)
Held by Institutions 110.7 (%)
Shares Short 2,270 (K)
Shares Short P.Month 1,730 (K)
Stock Financials
EPS -0.08
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.71
Profit Margin -1.7 %
Operating Margin 19.5 %
Return on Assets (ttm) -1.3 %
Return on Equity (ttm) -1.6 %
Qtrly Rev. Growth 23.2 %
Gross Profit (p.s.) 0
Sales Per Share 4.08
EBITDA (p.s.) -0.04
Qtrly Earnings Growth 104.5 %
Operating Cash Flow 35 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -743.15
PEG Ratio 0
Price to Book value 11.02
Price to Sales 12.74
Price to Cash Flow 71.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android